تحميل...
Preclinical rationale for use of the clinically-available multitargeted tyrosine kinase inhibitor crizotinib in ROS1 translocated lung cancer
HYPOTHESIS: Most clinically-available small molecule kinase inhibitors are multitargeted and can inhibit multiple kinases. Our driving hypothesis was that one of these multitargeted tyrosine kinase inhibitors (TKIs) would have anti-proliferative activity against ROS1 translocated non-small-cell lung...
محفوظ في:
| المؤلفون الرئيسيون: | , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
2012
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3378824/ https://ncbi.nlm.nih.gov/pubmed/22617245 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3182570919 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|